Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Tourmaline is now an indirect wholly owned subsidiary of Novartis
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
